Clinical Trials Logo

Filter by:
  • Withdrawn  
  • Page [1]
NCT ID: NCT04289558 Withdrawn - Falciparum Malaria Clinical Trials

Nitrite Infusion in Children With Malaria

Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety of intravenous sodium nitrite in African children who have moderately severe malaria.

NCT ID: NCT03265977 Withdrawn - Clinical trials for Tuberculosis Infection

A Phase II Study of H56:IC31 in Healthy Adolescents

A-043
Start date: June 2018
Phase: Phase 2
Study type: Interventional

This clinical trial will evaluate safety, immunogenicity, and efficacy (prevention of Mtb infection as measured by IGRA conversions) of H56:IC31 in remotely BCG vaccinated adolescents.

NCT ID: NCT02294214 Withdrawn - Malaria Clinical Trials

Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania

SR-M-Tz
Start date: February 2016
Phase: N/A
Study type: Interventional

The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of spatial repellent products in reducing the incidence of malaria infection in human cohorts. The null hypothesis (H0) is that there is no difference in malaria incidence between intervention and control arms.

NCT ID: NCT01255371 Withdrawn - HIV Clinical Trials

A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir

ALISA
Start date: March 2012
Phase: Phase 3
Study type: Interventional

In the well recognized context of HIV infection chronicity, it is now crucial to identify and evaluate effective, well tolerated and affordable second line regimen in resources limited countries where patients often change treatment after a long period of viral replication while on first line regimen. This multicentre international, randomized, non-blinded phase III trial aim to demonstrate the non-inferiority of a generic lamivudine-tenofovir-atazanavir/ritonavir regimen (daily intake) as compared to a standard emtricitabine-tenofovir-lopinavir/ritonavir (twice daily intake)regimen for second line HIV-1 treatment. by stratifying on the viral load level (between 1000 and 5000 copies/mL versus > 5000 copies/mL) at inclusion, this trial will also allow to evaluate the optimum moment for instituting the second-line treatment.